Wells Fargo
MAZE

Wells Fargo’s Maze Therapeutics MAZE Stock Holding History

Wells Fargo’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$956K Buy
32,047
+21,678
+209% +$568K ﹤0.01% 4141
2026
Q1 		$310K Sell
10,369
-13,639
-57% -$602K ﹤0.01% 4428
2025
Q4 		$995K Buy
24,008
+9,229
+62% +$317K ﹤0.01% 3976
2025
Q3 		$383K Buy
14,779
+9,164
+163% +$155K ﹤0.01% 4491
2025
Q2 		$68.9K Buy
5,615
+922
+20% +$9.59K ﹤0.01% 5391
2025
Q1 		$51.7K Buy
+4,693
New +$56.5K ﹤0.01% 5384

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Wells Fargo's MAZE Position: Q2 2026 in Review

Wells Fargo increased its Maze Therapeutics (MAZE) stake by 209% in Q2 2026, buying an estimated $568K and bringing the position to 32,047 shares worth $956K. The position accounts for ﹤0.01% of the portfolio, ranked #4141.

Wells Fargo first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. The position peaked at $995K in Q4 2025. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Wells Fargo held 32,047 shares of Maze Therapeutics worth $956K as of Q2 2026.
  • Wells Fargo bought 21,678 Maze Therapeutics shares in Q2 2026, an estimated $568K.
  • Maze Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4141 holding.
  • Wells Fargo first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Wells Fargo's Maze Therapeutics position peaked at $995K in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.